Results 201 to 210 of about 5,563 (240)

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. [PDF]

Clin Cancer Res
Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Hu X, Jurida G, Kouros-Mehr H, Janát-Amsbury MM, Eggert T, Tran B.   +28 more
europepmc   +1 more source

Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse. [PDF]

Leukemia
Kazerani M, Marcinek A, Philipp N, Brauchle B, Taylor JJ, Moreno HD, Terrasi A, Tast B, Rohrbacher L, Wang Y, Warm M, Emhardt AJ, Magno G, Spiekermann K, Herold T, Straub T, Theurich S, Schotta G, Kischel R, Bücklein VL, Subklewe M.   +20 more
europepmc   +1 more source

First‐in‐Human Dose Selection for T‐Cell Engaging Bispecific Antibodies

Clinical Pharmacology & Therapeutics
openaire   +3 more sources

Bispecific T-cell engagers in oral cancer immunotherapy

Oral Oncology Reports
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Bispecific T‐cell engagers for treatment of multiple myeloma

American Journal of Hematology, 2022
AbstractBispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for multiple myeloma (MM) target the B cell maturation antigen (BCMA) and differ among themselves ...
Gayathri Ravi, Luciano J. Costa
openaire   +2 more sources

Bispecific antibodies engage T cells for antitumor immunotherapy

Expert Opinion on Biological Therapy, 2011
Although considerable evidence supports the hypothesis that T cells play a critical role in the immune response against cancer, the ability to mount and sustain tumor-specific cellular responses in vivo remains a challenge. A strategy that harnesses the cytotoxic advantage of T cell therapy is the use of bispecific antibodies designed to engage and ...
Bryan D, Choi, Mingqing, Cai, Darell D, Bigner, Ankit I, Mehta, Chien-Tsun, Kuan, John H, Sampson   +5 more
openaire   +2 more sources

Blinatumomab: A novel, bispecific, T-cell engaging antibody

American Journal of Health-System Pharmacy, 2016
The pharmacology, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, safety and tolerability, and place in therapy of blinatumomab are reviewed.Blinatumomab is a novel, bispecific, T-cell engaging antibody that targets tumor-associated antigens CD19 and CD3.
Megan Brafford, May, Ashley, Glode
openaire   +2 more sources

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

Cancer Research, 2009
Abstract There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease. However, tumor-specific T-cell responses are difficult to mount and sustain in cancer patients, and are limited by numerous immune escape mechanisms of tumor cells selected ...
Patrick A, Baeuerle, Carsten, Reinhardt
openaire   +2 more sources

Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies

2019
Bispecific antibodies are an emerging novel therapeutic construct used to treat a variety of cancers. These drugs utilize a small fusion protein to link two single-chain antibodies, allowing for simultaneous binding of two different epitopes. Bispecific T-cell engagers (BiTE) are a subset of bispecific antibodies that bind the target antigen on the ...
Stacy L. Cooper, Patrick A. Brown
openaire   +1 more source

Quantitative Pharmacology Methods for Bispecific T Cell Engagers

Bulletin of Mathematical Biology
Abstract T Cell Engager (TCE)s are an exciting therapeutic modality in immuno-oncology that acts to bypass antigen presentation and forms a direct link between cancer and immune cells in the Tumor Microenvironment (TME). TCEs are efficacious only when the drug is bound to both immune and cancer cell targets.
Mahdiar Sadeghi, Irina Kareva, Gleb Pogudin, Eduardo D. Sontag   +3 more
openaire   +2 more sources